In a recent publication, the researchers assessed clinical data from 3,000 late-stage NSCLC patients after performing DNA and RNA sequencing on their tissue samples.
The test showed 90 percent sensitivity and 75 percent specificity in a 250-patient blinded study, even without the addition of clinical risk information.
Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.
Plans are in place for a Guardant360-based assay to predict response to AsztraZeneca's Tagrisso and for a blood-based TMB test using the larger GuardantOmni panel.
The company reported revenues of $21.7 million compared to $11.1 million in the year-ago quarter, overshooting analysts' expectations of $17.5 million.
The company reported no revenues in Q3 but said it has completed the transition to a new diagnostic platform for its DetermaVu liquid biopsy lung cancer test.
The assay can identify KRAS, NRAS, PIK3CA, BRAF, and EGFR gene mutations, as well as 19 gene rearrangements of the ALK, ROS1, RET, NTRK1, and MET genes from FFPE.
